Terapia nutrițională în fenilcetonurie

September 2010
Romanian Journal of Medical Practice;2010, Vol. 5 Issue 3, p174
Academic Journal
In phenylketonuria (PKU) -- a disease due to a deficit of phenylalanine hydroxylase, the only therapeutic modality accepted by international consensus is represented by diet. In recent years, the nutritional management has become more complex. The objective is to optimize patient's growth, development and diet compliance. The results of the treatment depends on the quality of control of plasma phenylalanine (Phe) in the first years of life and on the age at the start of treatment.


Related Articles

  • Survey of national guidelines for the treatment of phenylketonuria. Schweitzer-Krantz, Susanne; Burgard, Peter // European Journal of Pediatrics;2000, Vol. 159 Issue 14, pS70 

    Abstract Phenylketonuria treatment policies vary not only between different countries worldwide, but also within one country. Recommendations and guidelines for phenylketonuria should deal with the following subjects: 1. What is the target age to start dietary phenylalanine restriction under...

  • Neuropsychological approaches to treatment policy issues in phenylketonuria. Griffiths, Peter // European Journal of Pediatrics;2000, Vol. 159 Issue 14, pS82 

    Abstract Neuropsychological research conducted so far on treatment factors in phenylketonuria suggests that dietary cessation at age 6 is too early. However, continuation of diet until age 10 appears to provide protection against subsequent hyperphenylalaninaemia in the domains of perception,...

  • Tetrahydrobiopterin and Dietary Restriction in Mild Phenylketonuria. Seashore, Margretta R. // New England Journal of Medicine;12/26/2002, Vol. 347 Issue 26, p2094 

    The article presents the author's views on several studies conducted to explore the therapeutic efficacy of tetrahydrobiopterin in patients with phenylketonuria. According to the author, the disease is one of the first inborn errors of metabolism that could be diagnosed by newborn screening. A...

  • Comments on neuropsychological approaches to treatment policy issues in phenylketonuria. Stemerdink, Nanke B. A. // European Journal of Pediatrics;2000, Vol. 159 Issue 14, pS87 

    Comments on a study dealing with on neuropsychological approaches to treatment policy issues in phenylketonuria (PKU). Disagreement about the treatment of PKU patients; Two methodological issues that are important in the treatment of older patients; Deficits found in PKU patients that were...

  • 50 NUTRITIONAL HEALING TIPS.  // Prevention;Mar90, Vol. 42 Issue 3, p33 

    Presents tips for deterring, alleviating or healing various ailments through nutrition. Cookies for abdominal pain; Fishoil for rheumatoid arthritis; Caffeine in coffee as first aid for asthma; Vitamin D to lower risk of colon cancer; Sipping citrus fruit juices to spare teeth from acid bath.

  • Pharmacotherapy Options in the Management of Phenylketonuria. Peters, Stacy; Van Gilder, Deidra; Dvoracek, Kyle; Hegge, Karly A. // Clinical Medicine Insights: Therapeutics;2011, Issue 3, p327 

    Phenylketonuria (PKU) is an autosomal recessive disorder related to a deficiency in the enzyme phenylalanine hydroxylase (PAH), which converts phenylalanine to tyrosine. As a result, phenylalanine can accumulate in the bloodstream, potentially leading to severe neurologic sequelae....

  • Sapropterin. Sanford, Mark; Keating, Gillian M. // Drugs;2009, Vol. 69 Issue 4, p461 

    Sapropterin dihydrochloride (Kuvan®), hereafter referred to as sapropterin, is a synthetic formulation of the active 6R-isomer of tetrahydrobiopterin, a naturally occurring cofactor for phenylalanine hydroxylase. In the EU, sapropterin is approved for the treatment of hyperphenylalaninaemia...

  • Protein-Folding Diseases: Chaperones to the rescue. Hoyos Flight, Monica // Nature Reviews Drug Discovery;Sep2008, Vol. 7 Issue 9, p730 

    The article discusses the use of high-throughput screening approach to identify pharmacological chaperones for the treatment of phenylketonuria (PKU), an inherited metabolic disease caused by mutations that affect phenylalanine hydroxylase (PAH). It states that 1, 000 chemicals from a...

  • Nutrition, physical growth, and bone density in treated phenylketonuria. Przyrembel, Hildegard; Bremer, Hans-Joachim // European Journal of Pediatrics;2000, Vol. 159 Issue 14, pS129 

    Abstract Dietary treatment of phenylketonuria is well established to be safe and to prevent developmental and mental impairment in patients with low or absent phenylalanine hydroxylase activity. The use of semi-synthetic diets necessitates careful and longitudinal control not only of physical...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics